to study the effect and safety of two products in treatment of psoriasis.
Phase 4
Completed
- Conditions
- Health Condition 1: null- Clinically diagnosed localized, plaque psoriasis vulgaris or Palmoplanter psoriasis
- Registration Number
- CTRI/2012/09/003001
- Lead Sponsor
- Glenmark Pharmaceuticals Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
1.Subjects between 18 to 60 yrs ( treatment naïve patients or patients receiving treatments such as Corticosteroids, Methotrexate or PUVA should be given a wash out period of 10 days)
2.Clinically diagnosed localized, plaque psoriasis vulgaris or Palmoplanter psoriasis affecting maximum up to 10-20% of the total body surface area. The size of lesion selected is approximately 4 to 10 cm2
3.Subjects must provide written informed consent and comply to the protocol.
Exclusion Criteria
1.Subjects with psoriatic erythroderma, generalized pustular psoriasis
2.Pregnancy & Lactation
3.Concomitant tuberculosis
4.Syphilis
5.Uncontrolled Diabetes mellitus
6.Leukemia
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Investigatorâ??s clinical assessment on LPSI score to evaluate reduction of erythema, scaling, thickness. <br/ ><br>2.Assessment of Pruritus <br/ ><br>3.Global Evaluation <br/ ><br>4. Subjects observation <br/ ><br> <br/ ><br>Timepoint: 0day- 7days- 14 days <br/ ><br>
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI